GHK-Cu Tripeptide Permeates and Deposits in Human Skin Ex Vivo, Suggesting Transdermal Anti-Inflammatory Potential
Background
Inflammatory skin diseases represent a broad therapeutic target where local delivery of bioactive agents can reduce systemic side effects. Copper plays a critical role in tissue remodeling and anti-inflammatory signaling, and GHK-Cu — a naturally occurring human plasma tripeptide — has been studied for its capacity to modulate inflammatory cascades and promote wound healing. However, whether topically applied GHK-Cu can penetrate beyond the stratum corneum to reach viable epidermis and dermis in pharmacologically relevant quantities has remained uncharacterized. Understanding transdermal penetration depth and tissue retention is essential before any clinical anti-inflammatory protocol can be rationally designed around this compound.
Study Design
Glycyl-L-histidyl-L-lysine cuprate diacetate (0.68% aqueous copper) was applied under infinite dose conditions using flow-through diffusion cells with 1 cm² exposure area across three distinct skin preparations: isolated stratum corneum, heat-separated epidermis, and full dermatomed human skin. Receptor fluid was collected at 4-hour intervals over 48 hours and analyzed by inductively coupled plasma mass spectrometry (ICP-MS) for quantification of copper. Copper was also measured in retained tissue fractions. No control arm or comparative formulation was described in the abstract.
Results
Copper applied as GHK-Cu penetrated all skin preparations tested in the in vitro model. Through dermatomed skin, the permeability coefficient was 2.43 ± 0.51 × 10⁻⁴ cm/h, a value consistent with moderate transdermal permeability for a metallopeptide complex.
136.2 ± 17.5 μg/cm² of copper permeated 1 cm² of dermatomed skin over 48 hours, while 82 ± 8.1 μg/cm² was retained within the tissue as a depot.
The combination of active permeation and significant tissue retention indicates that GHK-Cu does not simply deposit superficially on the stratum corneum but distributes into deeper viable skin layers. The depot formation of 82 μg/cm² is particularly notable, as it suggests a reservoir effect that could sustain local copper bioavailability over time — potentially relevant to chronic inflammatory conditions. The authors concluded that the amounts permeated and retained are potentially effective for the treatment of inflammatory diseases, though no direct inflammatory biomarker data were reported in this permeation study.
Key Findings
- Permeability coefficient through dermatomed skin: 2.43 ± 0.51 × 10⁻⁴ cm/h
- 136.2 ± 17.5 μg/cm² copper permeated 1 cm² of dermatomed skin over 48 h
- 82 ± 8.1 μg/cm² copper retained in dermatomed skin as a tissue depot
- GHK-Cu was tested across three skin layers: stratum corneum, epidermis, and dermatomed skin
- ICP-MS used to quantify copper in receptor fluid and tissue fractions at 4 h intervals
Why It Matters
Topical GHK-Cu formulations can deliver copper into viable skin tissue at measurable quantities, validating the transdermal route as pharmacologically plausible — not merely cosmetic. For clinicians and formulators, the depot effect (~82 μg/cm² retained) implies that intermittent application could sustain local concentrations without continuous dosing. For biohackers and peptide users currently applying GHK-Cu serums, these data provide the first mechanistic rationale that copper actually penetrates beyond the stratum corneum under controlled ex vivo conditions. Full clinical translation will require in vivo studies confirming anti-inflammatory efficacy at these tissue concentrations, meaning current protocols remain empirical pending pharmacodynamic confirmation.
TitrateLab articles covering GHK-Cu
Written by TitrateLab, separately from the study summarized above.
